BCG vaccination  in Hodgkin's lymphogranuloma.
Results of active non-specific immunotherapy in 25 patients suffering from Hodgkin's disease are given. All of them, being at the stage of a complete remission (residual disease) were divided into two groups according to the clinical stage: group 1 at the stage I and II and group 2 at the stage III and IV. To each vaccinated patient a non-vaccinated control, being at the same stage of disease and of approximately the same age, was selected by applying the method A--B. Results as to the survival time and the remission duration were in both vaccinated groups significantly longer although less significant in patients with an advanced stage of the disease. The present report is to be considered preliminary and the research work is carried on.
D001500:BCG Vaccine / Q000009:adverse effects / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008199:Lymphadenitis / Q000209:etiology; D012075:Remission, Spontaneous; D013997:Time Factors
D001500:BCG Vaccine